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ABSTRACT 
Objective: To evaluate the thrombolytic treatment in acute myocardial infarction (AMI) and to compare the costs and the effectiveness of Reteplase 
double-bolus vs Streptokinase in our clinic, to compare this data with other studies.  
Methods: Two thrombolytic treatments were compared; Reteplase and Streptokinase in AMI by following the patients during hospital stay and at 
certain periods of time of 6 months, 12 months and 24 months. Differences between the two groups (streptokinase and reteplase) for discrete 
variables were performed by the Student test for two samples and Hi-square test. Data analysis was performed with SPSS statistical package, 
version 18 
Results: The analysis showed no significant differences between the treatments regarding the effectiveness. After 6 months, 12 months and 24 
months observation, the survival rate was 96.4% for reteplase group and 96.9% for streptokinase group. The mean age was 64.29 years for 
reteplase group and 56.03 years for streptokinase group (p=0.001). Hospitalization in reteplase group was at an average of 13.04days, and in 
streptokinase group was at an average of 17.79days (p=0.01) 
Cost in each respective group was 90184.90 Lek (646€) and 54148.63 Lek (388€). The difference is 36036.27 Lek or 258€ (p=0.001). 
Conclusion: Both thrombolytics (reteplase and streptokinase) have similar effectiveness in treatment of Acute Myocardial Infarction. Reteplase is 
an effective drug in the treatment of clinically Acute Myocardial Infarction, but the cost of reteplase is higher than streptokinase. It is safe, easily 
applied and it will be a useful addition to the valid list of thrombolytic drugs. 
Keywords: Cardiovascular disease, Acute myocardial infarction, Thrombolytics, Tissue plasminogen activator (t-PA), Reteplase, Streptokinase, 
Cost-effectiveness, Lek= Albanian money. 
 
INTRODUCTION 
Acute myocardial infarction remains a leading cause of morbidity 
and mortality worldwide, caused by the complete occlusion of a 
coronary artery with thrombus [1]. The thrombus occurs at the site 
of a plaque which has ruptured, exposing its inner core and thus 
promoting thrombus formation.  
The goals of therapy in acute MI are the expedient restoration of 
normal coronary blood flow and the maximum salvage of functional 
myocardium. These goals can be met by a number of medical 
interventions and adjunctive therapies. The primary obstacles to 
achieving these goals are the patient's failure to recognize MI 
symptoms quickly and the delay in seeking medical attention. When 
patients present themselves at the hospital, there are a variety of 
interventions to achieve treatment goals [2]. 
Early treatment aims to reduce the extent of myocardial damage. As 
the myocardium is damaged by a diminished oxygen supply due to the 
obstructed coronary artery, infarct size can be reduced in two ways:  
• Dissolution of the thrombus to restore coronary blood flow 
• Decreasing myocardial oxygen consumption 
Thrombolytic therapy has been a major advance in the management 
of acute myocardial infarction. Thrombolytic therapy works by 
lysing infarct artery thrombs and achieving reperfusion, thereby 
reducing infarct size, preserving left ventricular function, and 
improving survival[3]. 
These drugs are most effective if administered immediately after 
infarct has been determined. The advantage of administration is 
highest within the first sixty minutes after a thrombotic event, but 
may extend up to six hours after the start of symptoms [4]. 
These drugs are often administered in combination 
with anticoagulant drugs such as intravenous heparin or low 
molecular weight heparin, for synergistic antithrombotic effects and 
secondary prevention.  
Streptokinase and alteplase are established therapies in acute 
myocardial infarction. Reteplase is a new thrombolytic agent that 
can be given as a double bolus [5]. 
The ‘first generation’ thrombolytics had clinical disadvantages such 
as low specificity for fibrin, increased risk of allergic reactions (in 
particular with streptokinase) and short half-life. Newer 
thrombolytic agents such as reteplase and tenecteplase have been 
developed with potential advantages that include: prolonged 
half-life, increased fibrin specificity and increased resistance to 
inhibition by plasminogen activators. However, these 
laboratory-measured advantages may not translate into measurable 
clinical benefits [6]. 
It was proved that there is no significant difference between 
reteplase and streptokinase: reteplase reduced absolute 35-day 
mortality by 0.51% (NS, 95%CI 0.96% to 1.98%). At the lower 
extreme therefore, this fits within the definition of equivalence and 
therefore it may be said that reteplase is no worse than 
streptokinase INJECT study [7]. 
Although clear differences between thrombolytic agents are evident 
in the speed with which the agents achieve reperfusion, the similar 
survival rates in these previous trials suggested that factors other 
than rapid or sustained coronary reperfusion might be important in 
reducing mortality [8]. 
Reteplase produced rapid and effective coronary artery 
thrombolysis in a number of dose-finding and comparative studies. 
Double-bolus administration of reteplase 10U+10U produced 
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significantly higher coronary artery patency rates than accelerated 
alteplase (100 mg as a 1.5-hour infusion) in patients with AMI in the 
RAPID-II study [9].  
By other studies, it was proved that there were no significant 
differences between reteplase and streptokinase following up 6-
months post AMI treatment [10].  
At 1-year follow-up, survival status was ascertained in 97.4% of the 
15 059 patients enrolled in the GUSTO-III trial. At 1 year, the 
mortality rate for the t-PA–assigned group was 11.06%, and for r-PA 
it was 11.20% (P= 0.77). The absolute mortality difference of 0.14% 
has 95% CIs of 21.21% to 0.93%. There were no significant 
differences in outcome by intention-to-treat for the 2 different 
plasminogen activators in the pre specified groups (age, infarct 
location, time-to-treatment). The absolute difference in mortality 
rates between t-PA and r-PA progressively narrowed over the 
predetermined observation times after random assignment; it was 
0.31% at 24 hours, 0.26% at 7 days, 0.23% at 30 days, and 0.14% at 
1 year. Of note, mortality rate in the trial between 30 days and 1 year 
in 13 883 patients was 4.02% and did not differ between the 
treatment groups [11]. 
While the morbidity and mortality from acute myocardial infarction 
is too high, finding out cost-effective treatments is the goal of the 
clinicians. 
The aim of this study is to evaluate thrombolytic cost-effectiveness 
therapy in acute myocardial infarction in an intensive care hospital 
in Tirana as a better choice to reduce mortality, calculation of the 
hospital treatment cost and finally finding out the cost-effective 
treatment. This cost-effectiveness analyse will be a novel solution for 
hospital treatments here in Albanian hospitals where cardiology 
intensive care is offered. 
This trial was designed to determine whether the effect 
of reteplase on survival was at least equivalent to that of a 
standard streptokinase 
Differences between the two groups (streptokinase and reteplase) 
for continuous quantitative variables were performed by the 
Student test for two independent samples. 
regimen. 
MATERIALS AND METHODS 
In our study 120 cases were included with acute myocardial 
infarction (AMI); 56 cases treated with Reteplase and 64 cases 
treated with Streptokinase in the period 2010-2013. Data was 
obtained by clinical records in Intensive Care Clinic of the University 
Hospital Centre "Mother Teresa". The selection is made randomly in 
the both treated groups. Observation in time is achieved by 
contacting the patients on phone and interviewing them. The 
patients are followed up in hospital stay, 6 months after 
hospitalization, 12 months and after 24 months after hospitalization.  
There was not included the patients with contraindications of 
thrombolytics. There was collected data about the condition of the 
patients, the duration of hospitalisation, the therapy for each patient. 
We evaluate the total cost of medicaments used for each patient. A 
cost-effectiveness analyse was performed for each group.  
Statistical analysis 
Continuous data were presented at the average value and standard 
deviation. 
Discrete data were presented in absolute value and as percentages. 
Differences between the two groups (streptokinase and reteplase) 
for discrete variables were performed by the Student test for two 
samples and Hi-square test. 
Data analysis was performed with SPSS statistical package, version 
18. 
RESULTS 
The study enrolled a total of 120 patients, 18 females (15 %) and 
102 males (85) diagnosed with AMI. The results are shown below by 
tables and figures.  
 
 
Fig. 1: It shows comparing results by gender in both groups 
 
This fig. shows that acute myocardial infarction affects more men 
than women. In streptokinase group 93.8% are men and 6.2% of the 
patients are women; in reteplase group 75% are men and 25% 
women. 
The table (1) indicates that there are not statistically significant 
differences in death of the patients in both groups. Group treated 
with Reteplase had one case of death, mortality (3.6%) within 30 
days (hospital rehabilitation), the group treated with Streptokinase 
had one case of death, mortality (3.1%). Our results are equivalent 
to those at INJECT study [7]. 
Table (2) shows the effectiveness of each group after 6 months, 12 
months, and 24 months post AMI treatment. Survival rate after 6 
months, 12 months and 24 months after thrombolytic therapy does 
not differ in the both groups. In reteplase group no one feel bad, 
while in streptokinase group 6.4% of patients feel bad; 71.4 % of 
patients in reteplase group feel good vs. 54.8% in streptokinase 
group; 25% feel very good in reteplase group vs. 38.6% in 
streptokinase group. These results show no important differences. 
Likewise, no significant difference was apparent between the 
reteplase and streptokinase groups
Table (3) shows a statistically significant differences between the 
group with streptokinase related reteplase group, mean age 
56.03±8.71 in streptokinase group vs. 64.29±10.03 in reteplase 
group, P=0.001. Reteplase group has an average hospital 
rehabilitation of 13.4 days, and the streptokinase group 17.97 days 
with a difference of 4.57 days, (p=0.01). There is a statistically 
significant difference between the group of streptokinase and 
Reteplase related to the total cost of treatment (p =0.001), where the 
total average cost in Reteplase group is 658.5 €/patient and 386.8 
€/patient in streptokinase group, with a difference of 271.7€. 
 regard 6-month mortality post 
AMI. 
 
Table 1: It shows the situation at the end of hospital treatment 
 Treatment Total (N=120) 
Reteplase (N=56) streptokinase (N=64) 
Condition after treat dead 1 1 2 
3.6% 3.1% 3.3% 
improved 55 63 118 
96.4% 96.9% 96.7% 
 
Rama et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 6, 180-183 
182 
Table 2: It shows comparison between thrombolytics during a period of time 
 Treatment Total 
Reteplase (N=56) streptokinase (N=64) 
Condition after 6months dead 1 (3.6) 1 (3.1) 2 (3.3) 
No good 0 (0.0) 2 (6.3) 2 (3.3) 
good 41 (71.4) 37 (53.1) 78 (61.7) 
Very good 14 (25.0) 24 (37.5) 38 (31.7) 
Condition after 1 year dead 1 (3.6) 1 (3.2) 2 (3.3) 
No good 0 (0.0) 2 (6.4) 2 (3.3) 
good 41 (71.4) 37 (54.8) 78 
(61.7) 
Very good 14 (25.0) 24 (38.6) 38 (31.7) 
Condition after 2 years dead 1 (3.6) 1 (3.2) 2 (3.3) 
No good 0 (0.0) 2 (6.4) 2 (3.3) 
good 41 (71.4) 37 (54.8) 78 
(61.7) 
Very good 14 (25.0) 24 (38.6) 38 
(31.7) 
 
Table 3: It shows the comparison between age, total cost of treatment and hospital stay duration 
 treatment Nr of cases Mean SD SE t df Value p 
age Reteplase 56 64.29 10.03 1.89 3 58 0.001 
Streptokinase 64 56.03 8.71 1.54    
hospitalization Reteplase 56 13.04 5.92 1.12 -3 58 0.010 
Streptokinase 64 17.97 8.14 1.44    
Total cost Reteplase 56 92184.90 11191.19 2114.94 12 58 <0.001 
Streptokinase 64 54148.63 13693.78 2420.74    
 
 
Fig. 2: It shows the mean age in both groups 
 
Fig. (2) shows the comparison of age in two groups, where reteplase 
group has the higher mean age than streptokinase group. Older 
patients are treated with reteplase. 
 
 
Fig. 3: It shows the hospital rehabilitation stay in both groups 
Fig. (3) shows that Streptokinase group has longer hospital stay than 
reteplase group. 
There is a statistically significant difference between the group with 
Reteplase and streptokinase related hospital rehabilitation 13.04 
days vs. 17.79 days (p = 0.01), where the group with Reteplase has 
an average hospital stay fewer than group with streptokinase 
 
 
Fig. 4: It shows cost treatment comparison 
 
Fig. (4) presents difference between the group of streptokinase and 
Reteplase related to the total cost of treatment. Reteplase group has 
a total treatment cost of 92184.9lek vs. 54148.63 Lek in 
streptokinase group, or 685.5 € vs. 386.8 € with a difference of 
271.7 € (p<0.001), where the average total cost of Reteplase group 
is higher than that of streptokinase group. 
DISSCUSION 
Data from the available clinical trials suggest that reteplase is a fast-
acting and effective thrombolytic treatment for patients with AMI. r-
PA given as a double bolus of 10+10 MU achieves more rapid, 
complete, and sustained thrombolysis of the infarct-related artery 
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than standard-dose TPA, without an apparent increased risk of 
complications. This was associated with improved global and 
regional left ventricular function at hospital discharge [11, 12]. 
We evaluated the treatments with reteplase and streptokinase, 
comparing the both therapies during hospital stay, the survival and 
the cost treatments. It was estimated that reteplase is better 
tolerated than SK in older patients mean age 64.29±10.03 vs. 
56.03±8.71 (P=0.001) and hospitalization period 13.04days vs. 
17.97 days (P=0.01). 
In the INJECT–study there were 270 deaths (9.02%) in the reteplase 
and 285 deaths (9.53%) in the streptokinase group, a non-significant 
difference (95% CI-1.98% to 0.96%)[6,8]. Among patients who 
received treatment (98.8%) there were 263 deaths (8.90%) in the 
reteplase compared with 279 deaths (9.43%) in the streptokinase 
group (a difference of-0.53%). Because the upper limit of the 90% CI 
for this difference is 0.71%, this result shows that reteplase is at 
least as effective as streptokinase [13-16].  
In a study comparing directly the thrombolytics it is confirmed that 
there is no difference between reteplase and streptokinase (absolute 
difference in mortality of 0.53% vs. ITT analysis of 0.51%) [17].  
Regarding the mortality in our study, there were no significant 
changes in both groups (it was one dead patient (3.6% and 3.1%). 
Group treated with reteplase has the lead in terms of age, where 
effective treatment has emerged in greater age (mean age 64.29 
versus 56.03) p = 0.001.  
The simple double-bolus regimen of reteplase administration may 
permit earlier initiation of thrombolysis with fewer dosing errors 
than with continuous infusion regimens and thus afford a reduction 
in the morbidity and mortality risks in patients with acute 
myocardial infarction [18]. 
Reteplase treatment is simple and quick to realize and time recovery 
is shorter (average hospitalization13.4). Survival time in both 
groups is relatively flat, which shows almost identical performance 
between the two treatments. 
CONCLUSION 
As a conclusion thrombolytic therapies are more successful in Acute 
Myocardial Infarction treatment. They improve life quality and 
reduce mortality. Reteplase is at least as effective as streptokinase. 
So Reteplase(r-Pa) is an effective drug in the treatment of clinically 
Acute Myocardial Infarction. It is safe, easily applied and will be a 
useful addition to the valid list of thrombolytic drugs. 
The treatment cost of reteplase is higher compared with 
streptokinase and it should be estimated the cost/life saved as well.  
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